biology-technology-1/neurogesx-reports-second-quarter-2009-results-13446-5/;msg18067;topicseen

[0] Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results [0] Martek to Announce Fourth Quarter and Fiscal Year 2009 Results [0] Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities [0] Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option

Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2 Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3 Mirixa Corporation Announces Key New Hires 12958 1 Mirixa Corporation Announces Key New Hires 12958 2 Landmark project to map genomics of complex ant systems 9188 1 Landmark project to map genomics of complex ant systems 9188 2 European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 1 European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 2

[0] Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing [0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program